Loading stock data…
Liquidia Corporation (LQDA)
$86.22-2.81 (-3.16%)
Market ClosedLast close Jul 24
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Liquidia Corporation in the Healthcare sector is trading at $86.22 with a market capitalization of $6.2B. Wall Street consensus targets $84.88 (8 analysts), implying a -1.6% move over the next 12 months. The stock is currently near its 52-week high of $91.10, remaining 98.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $132.87M↑ | $92.02M↑ | $54.34M↑ | $8.84M↑ | $3.12M |
| Gross Profit | $121.01M↑ | $84.97M↑ | $51.17M↑ | $7.34M↑ | $1.60M |
| Operating Income | $61.50M↑ | $19.79M↑ | $1.77M↑ | -$37.51M↓ | -$35.42M |
| Net Income | $52.86M↑ | $14.55M↑ | -$3.53M↑ | -$41.58M↓ | -$38.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.54%
Volume
Today's trading volume
1.37M
Recent News
Liquidia (LQDA) Rallies As Fair Value Debate Turns On Growth And Patent Risk
What Recent Moves In Liquidia Stock May Be Telling Investors Liquidia (LQDA) has drawn investor attention after a period of strong share-price volatility, with returns over the past month, past 3 months, and year all moving meaningfully compared with prior levels. See our latest analysis for Liquidia. Recent trading in Liquidia reflects strong momentum, with a 30 day share price return of 14.14% and a 90 day share price return of 131.09%, alongside a very large 1 year total shareholder return...
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, ET & PBF
Liquidia, Energy Transfer and PBF Energy offer low-beta exposure as oil-driven volatility rises, backed by growth, stable fees and refining demand.
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.